Interim Consolidated Statement of Cash Flows (Unaudited) (USD $) In Millions	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Cash Flows from Operating Activities
Net income	$ 4,849	$ 1,482
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	5,566	5,515
Intangible asset impairment charges	461	216
Equity income from affiliates	(354)	(417)
Dividends and distributions from equity affiliates	186	264
Gain on AstraZeneca asset option exercise		(443)
Deferred income taxes	(974)	(743)
Share-based compensation	287	400
Other	(207)	227
Net changes in assets and liabilities	(664)	782
Net Cash Provided by Operating Activities	9,150	7,283
Cash Flows from Investing Activities
Capital expenditures	(1,120)	(1,018)
Purchases of securities and other investments	(4,686)	(5,826)
Proceeds from sales of securities and other investments	4,740	3,726
Dispositions of businesses, net of cash divested	323
Acquisitions of businesses, net of cash acquired	(373)	(152)
Proceeds from AstraZeneca option exercise		647
Other	(90)	133
Net Cash Used in Investing Activities	(1,206)	(2,490)
Cash Flows from Financing Activities
Net change in short-term borrowings	1,356	1,573
Payments on debt	(1,277)	(689)
Purchases of treasury stock	(1,359)	(1,593)
Dividends paid to stockholders	(3,526)	(3,559)
Proceeds from exercise of stock options	194	313
Other	(61)	(191)
Net Cash Used in Financing Activities	(4,673)	(4,146)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	82	(84)
Net Increase in Cash and Cash Equivalents	3,353	563
Cash and Cash Equivalents at Beginning of Year	10,900	9,311
Cash and Cash Equivalents at End of Period	$ 14,253	$ 9,874